4月7日 - ** 制药商Fennec Pharmaceuticals FENC.O股价盘前上涨2%至6.54美元
** 该公司称，一项新的研究已开始测试其药物PEDMARK对青少年、青年和成年顺铂患者听力损失的预防作用
** 顺铂是一种常见的化疗药物，可造成永久性听力损伤
** 公司称，该药物已在美国获批用于局部实体瘤儿童患者，并得到了青少年和年轻成人患者癌症治疗指南的支持
** 研究将跟踪 PEDMARK 是否能降低头颈部和睾丸癌成年患者的听力损伤，以及它如何影响顺铂从体内的清除 - FENC
** 表示正在与监管机构讨论将药物标签扩大到更多患者群体的计划
** 截至上一交易日收盘，股价年累计下跌约 17%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.